Biological Activity:
A tyrosine kinase inhibitor (TKI), targeting VEGFR/PDGFR/c-KIT; orally bioavailable drug exerting an anti-angiogenic effect.
LG Wilmes et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn. Reson. Imaging 2007, 25(3), 319-27.
HS Rugo et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 2005, 23(24), 5474-83
AG-01373是一种口服多受体酪氨酸激酶抑制剂,对血管内皮生长因子(VEGF)、血小板生长因子蛋白受体均有显著的抑制作用。 美国加州大学旧金山分校等就AG–013736对晚期固体瘤患者的治疗效果进行I期临床研究。
临床II期分类:实验性多效酪氨酸激酶抑制剂适应症状:黑色素瘤及肺癌、甲状腺癌、胰腺癌和卵巢癌,其衍生物AG-013958处于中期开发阶段,用于黄斑变性的治疗。
敬请关注:
联系人:杨建辉
400电话:4006551678
办公电话:021-50724187
传真:021-50724961*8006
手机:15921799099
企业QQ: 4006551678
邮箱:info@78bio.com
网址:http://www.qfbio.com/
地址:上海市浦东新区绣川路561号1102室
|